- Reuters•1 hour ago
PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.
- The Wall Street Journal•11 hours ago
The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products.
- The Wall Street Journal•yesterday
Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug ...
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||75.38 - 76.69|
|52 Week Range||62.50 - 79.07|
|PE Ratio (TTM)||23.25|
|Dividend & Yield||3.35 (4.12%)|
|1y Target Est||N/A|